Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough

开发用于治疗慢性咳嗽的 Nav1.7 选择性抑制剂

基本信息

  • 批准号:
    10258238
  • 负责人:
  • 金额:
    $ 67.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-05-01 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Chronic cough, or cough that persists for more than eight weeks, is a condition that is often associated with diseases such as chronic obstructive pulmonary disorder (COPD), asthma, idiopathic pulmonary fibrosis, bronchiectasis or gastroesophageal reflux disease (GERD). In other cases, the etiology is unknown, although it has been noted that the cough often first arises following a severe viral respiratory infection. Chronic cough has significant physical, psychological, social and economic consequences that negatively impact quality of life. Prevalence in the United States is as high as 11%, and in a majority of cases the condition is refractory. Compelling evidence supports the hypothesis that chronic cough arises from alterations in sensory physiology that cause hypersensitivity to previously innocuous stimuli. The voltage-gated sodium ion channel NaV1.7 is highly expressed in unmyelinated vagal nerve afferents that trigger cough through a sensorimotor reflex circuit. Results from a published pre-clinical report show that reducing expression of NaV1.7 nearly abolishes cough evoked by inhaled irritants, indicating that it is a promising target for reducing cough. SiteOne Therapeutics has discovered potent and selective small molecule inhibitors of NaV1.7 that block vagal C fiber activity in a dose-dependent manner. During a Phase 1 program, our team demonstrated that systemic administration of an isoform-selective NaV1.7 inhibitor abolishes the cough response to inhaled irritants in conscious guinea pigs. The objective of our Phase 2 program is evaluate safety, pharmacokinetic and efficacy endpoints, and to advance an inhaled NaV1.7 inhibitor into IND-enabling development as a therapeutic for chronic cough.
项目摘要 慢性咳嗽,或持续超过八周的咳嗽,是一种通常与 慢性阻塞性肺病(COPD)、哮喘、特发性肺纤维化 支气管扩张或胃食管反流病(GERD)。在其他情况下,病因不明,虽然它 已经注意到,咳嗽通常首先在严重的病毒性呼吸道感染之后出现。慢性咳嗽有 严重的身体、心理、社会和经济后果,对生活质量产生负面影响。 在美国的患病率高达11%,在大多数情况下,这种情况是难治性的。 令人信服的证据支持这一假设,即慢性咳嗽是由感觉器官的改变引起的。 对以前无害的刺激产生超敏反应的生理学。电压口控钢离子通道 NaV1.7在通过感觉运动触发咳嗽的无髓鞘迷走神经传入中高度表达 反射电路来自已发表的临床前报告的结果显示,NaV1.7表达的降低几乎 消除由吸入刺激物引起的咳嗽,表明它是减少咳嗽的有希望的靶点。SiteOne Therapeutics已经发现了阻断迷走神经C纤维的NaV1.7的有效和选择性小分子抑制剂 活性呈剂量依赖性。在第一阶段计划中,我们的团队证明了系统性 同种型选择性NaV1.7抑制剂的给药消除了哮喘患者对吸入刺激物的咳嗽反应, 清醒的豚鼠我们的2期项目的目的是评估安全性、药代动力学和疗效 终点,并将吸入性NaV1.7抑制剂推进IND使能开发,作为慢性 咳嗽.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Cureton Hunter其他文献

John Cureton Hunter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Cureton Hunter', 18)}}的其他基金

Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders
开发一种有效且高选择性的 NaV1.7 抑制剂,用于治疗急性疼痛,目标是减少阿片类药物的使用和预防阿片类药物使用障碍
  • 批准号:
    10025176
  • 财政年份:
    2019
  • 资助金额:
    $ 67.76万
  • 项目类别:
Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough
开发用于治疗慢性咳嗽的 Nav1.7 选择性抑制剂
  • 批准号:
    10402901
  • 财政年份:
    2019
  • 资助金额:
    $ 67.76万
  • 项目类别:

相似海外基金

Un/kindness, shame & resistance: the care of inpatients in NHS adult acute mental health units and how it might be improved
Un/善良,羞耻
  • 批准号:
    2885806
  • 财政年份:
    2023
  • 资助金额:
    $ 67.76万
  • 项目类别:
    Studentship
Post-Acute Care Transitions for Older Adult Medicare Beneficiaries with Serious Mental Illness
患有严重精神疾病的老年医疗保险受益人的急性后护理过渡
  • 批准号:
    10772386
  • 财政年份:
    2023
  • 资助金额:
    $ 67.76万
  • 项目类别:
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
  • 批准号:
    474619
  • 财政年份:
    2022
  • 资助金额:
    $ 67.76万
  • 项目类别:
    Operating Grants
Investigating the impact acute inhalation of cannabis with a high content of delta-9-tetrahydrocannabinol has on myelination and microglia in adult and aged mice
研究急性吸入高含量 delta-9-四氢大麻酚的大麻对成年和老年小鼠髓鞘形成和小胶质细胞的影响
  • 批准号:
    485965
  • 财政年份:
    2022
  • 资助金额:
    $ 67.76万
  • 项目类别:
    Studentship Programs
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
  • 批准号:
    466358
  • 财政年份:
    2022
  • 资助金额:
    $ 67.76万
  • 项目类别:
    Operating Grants
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
预测顺铂介导的急性肾损伤的代谢组学:加拿大多中心成人和儿童研究
  • 批准号:
    402040
  • 财政年份:
    2019
  • 资助金额:
    $ 67.76万
  • 项目类别:
    Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    $ 67.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Causal effect of time-varying driving pressures on mortality in mechanically ventilated, adult patients with acute respiratory distress syndrome
时变驱动压力对机械通气成年急性呼吸窘迫综合征患者死亡率的因果影响
  • 批准号:
    377313
  • 财政年份:
    2017
  • 资助金额:
    $ 67.76万
  • 项目类别:
    Studentship Programs
Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia
SETBP1 在成人 Ph 急性淋巴细胞白血病中的作用
  • 批准号:
    9315111
  • 财政年份:
    2016
  • 资助金额:
    $ 67.76万
  • 项目类别:
Acute Inhibition of Adult-born Granule Cells and its Effect on Antidepressant Act
成体颗粒细胞的急性抑制及其抗抑郁作用
  • 批准号:
    8734273
  • 财政年份:
    2013
  • 资助金额:
    $ 67.76万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了